Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. - Wikidata - awgldk - TriplyDB

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

http://www.wikidata.org/entity/Q42081736

about

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies The bone marrow microenvironment in Waldenström macroglobulinemia Cell labeling approaches for fluorescence-based in vivo flow cytometry Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability In vivo flow cytometry: a horizon of opportunities.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.SDF-1 inhibition targets the bone marrow niche for cancer therapy.PAK1 mediates resistance to PI3K inhibition in lymphomas.Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.New Therapeutic Approaches for Waldenstrom Macroglobulinemia Metastasis-associated gene, mag-1 improves tumour microenvironmental adaptation and potentiates tumour metastasis.Novel agents in Waldenström macroglobulinemia.Defining the role of TORC1/2 in multiple myeloma.Novel agents in Waldenstrom Macroglobulinemia.Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives Jolkinolide B from Euphorbia fischeriana Steud induces apoptosis in human leukemic U937 cells through PI3K/Akt and XIAP pathways.Emerging drugs for Waldenström's macroglobulinemia.The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.Utility of mTOR inhibition in hematologic malignancies.Targeting the bone marrow in Waldenstrom macroglobulinemia.AKT as locus of cancer positive feedback loops and extreme robustness.The bone marrow microenvironment in waldenstrom macroglobulinemia.Novel treatment options for Waldenström macroglobulinemia Waldenström macroglobulinemia: from biology to treatment.Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.The interaction of Wnt-11 and signalling cascades in prostate cancer.

P2860

Q26829652-44F5D1B9-7149-4C55-A824-28D2FE0ECA3E Q27028214-BC87F989-CEDB-40D9-BE1F-F1F8214CAE52 Q27693903-2C778895-ECE1-44F1-B0AA-CDABB6CCF4E6 Q28538024-07F8D36E-2E60-4C2A-B3B0-011E17B55069 Q30454382-F928947E-7889-499A-8702-7DCC14150099 Q33414529-E2305DF8-FCC0-4F27-9F1B-8C7B60AD995C Q34000632-20123E1F-1C44-412E-B33A-D02004210D65 Q34038031-1B1F843E-6323-489B-B1F7-41FF2A02A787 Q34164289-70720269-7944-4C1E-A47B-01BDBD0F0FB5 Q34188530-CEC01DE0-27E2-4839-B85E-D6F77F6D36BB Q34324830-759E90BC-143C-470D-A5B8-B7D9A4F3369E Q34539577-2E056203-3852-43E4-A30A-666AFB8E852B Q34682072-4983B6D5-E462-42F6-A115-894C47412495 Q34758583-7B3F8CC4-8687-4BD0-9D7D-D9277EEA8C6D Q34810176-3FBE4366-60F5-41DC-9D90-6762F3EB6B9E Q35176177-AFA760D9-E5C7-449A-B458-01D9AAAD246D Q35370402-513EF29A-84FB-4E54-9F40-E02AF1E1102B Q35429544-B3FCCF7B-1F86-40A4-B5BC-88204E65CADD Q35631315-D5844C2C-F0C6-463D-98DC-52EA9E29DF73 Q36117791-4872E14B-8080-41B0-8C07-2A5E52F08DE1 Q36211281-E6B54612-3A44-405A-ACEC-570F50E28257 Q36533710-2DA7E6E0-44D0-4588-BD03-79C9A2589382 Q36965860-B3A2C3DC-05E6-41B1-B3EA-F289B6A12BA9 Q37061428-DCA18EC2-31C9-4FE0-AFC6-95CB3CFE51FA Q37127055-D7141D8B-CF6E-4826-9563-4072F4527DEA Q37132788-15A1BE2B-BCE1-4CAC-A4F3-87416B16CDF5 Q37461369-9491FA97-7C82-42AA-95FF-409C102DD26A Q37847176-8282E71A-638E-470B-AEBC-13F440370971 Q37877729-3717602E-77EE-490F-858D-C83297777DB2 Q37883723-675730E3-C413-4EBF-B044-7C61CC0F58AE Q37950586-21A7FEBF-8F49-4CF1-A24A-9A92A7ED4389 Q38029572-47C2B524-6898-4305-9D0D-DA66B31A7228 Q38095959-06B90A63-312B-4D94-AF39-6F3701634576 Q38167433-1176A9BE-02B9-4439-ABAF-871E02123983 Q38176969-F61B12BE-1F35-4096-A5D0-08FECAE6E652 Q38212951-DF09B92C-DDC4-4C33-8307-3BA289D87C8B Q38425940-EF6B6DFF-3877-4F2E-827A-F6023C73E53F Q38551391-4D03C4C4-2485-4FB7-8580-BB35260C6D91 Q38760522-E372077D-B4B5-4E4E-B3CC-A8C9FD11316D Q38924969-DA27570A-5A9F-4D06-9B58-113C44B29C6E

P2860

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

http://www.wikidata.org/entity/Q42081736

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Dual targeting of the PI3K/Akt ...... Waldenstrom macroglobulinemia.

@en

Dual targeting of the PI3K/Akt ...... Waldenstrom macroglobulinemia.

@nl

type

label

Dual targeting of the PI3K/Akt ...... Waldenstrom macroglobulinemia.

@en

Dual targeting of the PI3K/Akt ...... Waldenstrom macroglobulinemia.

@nl

prefLabel

Dual targeting of the PI3K/Akt ...... Waldenstrom macroglobulinemia.

@en

Dual targeting of the PI3K/Akt ...... Waldenstrom macroglobulinemia.

@nl

P1433

Q42081736-47D3ADA7-5608-418B-80E7-DFA54B6D4C44

P1476

Q42081736-101C4961-6297-4DBA-847E-3736EC527879

P2093

Q42081736-14C5E172-2CFE-47C8-ADD9-5869B02959A5

Q42081736-18DFA0B6-62C9-44ED-8DCC-BECB2FF0C565

Q42081736-3F08D3BE-C4E2-479A-9E0A-D154456EF6A3

Q42081736-56685FAD-67CE-48C5-AA91-1A67BAB753EA

Q42081736-65BE5A8F-A4A2-4463-9689-60E75D470848

Q42081736-90D53EA6-F10F-4F34-A573-212CDD2AE576

Q42081736-C64B688E-86F9-4BE4-9832-1A87DDFB2F93

Q42081736-D095A111-B404-4B55-9D01-B6370773FBA4

Q42081736-F0AD0AA4-ADFC-4E13-A894-981C780DE89C

Q42081736-F8F2A969-23F1-4D22-988F-4FFB12BFA616

P2860

Q42081736-0284ABDF-7F55-4795-BBE3-CE7371E0B9C7

Q42081736-0A7820FF-F3D8-43C6-A077-D906D9F694E0

Q42081736-0DB9E53F-6C2F-44DA-847E-385C136174CC

Q42081736-0EE99647-291A-4CF5-A526-F6FB3B8F7645

Q42081736-15A7407B-2D8A-45C5-AD13-B942FB9E7EF9

Q42081736-27EECB66-95CF-4C4C-B2A4-E0CC7AE2618C

Q42081736-3119787C-2C7E-484B-81AD-52BFA3B3B684

Q42081736-3B0F1755-E725-450D-9718-3F96AE592B89

Q42081736-3CF67A69-9908-4ECA-AFB8-9DE527A6880A

Q42081736-42354CFA-6155-4DDA-8422-83B0BB696D9F

P304

Q42081736-66EB5D35-2C68-4F1A-B551-4895DB9C5064

P31

Q42081736-9D3AFBB7-773A-4EBD-8579-49C69E0048BA

P356

Q42081736-20EEFB49-BCFC-474B-82A3-0663E9EF5920

P407

Q42081736-F7B4C925-7276-41B3-BE5B-FE1581DA9887

P433

Q42081736-27C5797E-1F1A-4744-B18C-3F65123803DC

P478

Q42081736-61715CA6-12DA-4D73-8B2C-FBDF9F7D3E4D

P50

Q42081736-0BF28D71-DDE3-4CEB-9550-71E63B34EED2

Q42081736-1FFBF26B-5EB4-4A21-A568-4EA0B86DD9F3

Q42081736-93DCB1A2-81FB-493C-AEB6-6EE50538E0B5

Q42081736-A6855427-893F-46FC-9697-B86C3842D7CE

Q42081736-DBA3B550-F407-4B2F-A9DF-5684ABA6B8D4

P577

Q42081736-40D33C68-B1FE-4501-B921-442ABF45FAAA

P5875

Q42081736-255520F5-B886-4AF0-B340-4621A3F9B5B0

P698

Q42081736-963C1335-F6A5-4E2F-B66B-14B97700EDD9

P932

Q42081736-D869A0B2-8992-40E3-8AE4-A5088CE0F35F

P356

BLOOD-2009-07-235747

P1433

P1476

Dual targeting of the PI3K/Akt ...... Waldenstrom macroglobulinemia

@en

P2093

Abdel Kareem Azab

http://www.w3.org/2001/XMLSchema#string

Charles Lin

http://www.w3.org/2001/XMLSchema#string

Costas Pitsillides

http://www.w3.org/2001/XMLSchema#string

Emanuel N Husu

http://www.w3.org/2001/XMLSchema#string

Feda Azab

http://www.w3.org/2001/XMLSchema#string

Hai T Ngo

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

Judith Runnels

http://www.w3.org/2001/XMLSchema#string

Molly Melhem

http://www.w3.org/2001/XMLSchema#string

Phong Quang

http://www.w3.org/2001/XMLSchema#string

P2860

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals.

FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

P304

559-569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-07-235747

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40452654

http://www.w3.org/2001/XMLSchema#string

P698

19965685

http://www.w3.org/2001/XMLSchema#string

P932

2810978

http://www.w3.org/2001/XMLSchema#string